One year observation of immunotherapy for Artemisia hay fever in China: a clinical and immunological study.
A controlled trial of one year immunotherapy was conducted in 50 Artemisia-sensitive hay fever patients (treatment group). From October 1985 to July 1986, all of the treatment group patients received one year regular injection of Artemisia pollen allergen extract totalling 30,000 protein nitrogen units (PNU). For these patients, symptom score indices of the posttreatment 1986 pollination season were compared with those from the pretreatment 1985 season and also with the scores of a similar group of 30 Artemisia-sensitive patients treated only with symptomatic medications during the 1986 season (control group). The 1986 symptom scores to the treatment group were significantly improved and the effective rate was 78%. Immunological study with the Human Basophil Degranulation Test (HBDT) showed a significant decrease in degranulation reactions after immunotherapy. Moreover, The decline of the HBDT positive rate in the treatment group was significantly greater in patients with improved symptoms than patients with unchanged symptoms. No difference was observed in basophil degranulation in those patients tested with a pollen-free plant extract, which was not applied in immunotherapy. The results suggested that immunotherapy could induce desensitization of basophils and that the induction might be allergen specific. Basophil desensitization may play an important role in the mechanism of immunotherapy.